Evidence map›Paper›PMID 39010308›Full record

ArticleACS applied materials & interfaces2024

Conditional Cell-Penetrating Peptide Exposure as Selective Nanoparticle Uptake Signal.

Melanie Walter, Merlin Bresinsky, Oliver Zimmer, Steffen Pockes, Achim Goepferich

Abstract read
In one paragraph

Article in ACS applied materials & interfaces, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Recent Advances and Future Prospects in Biological-Membrane-Targeted Polymers.Polymer science & technology (Washington, D.C.) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Melanie WalterDepartment of Pharmaceutical Technology, University of Regensburg, 93053 Regensburg, Bavaria, Germany.
Merlin BresinskyDepartment of Medicinal Chemistry I, University of Regensburg, 93053 Regensburg, Bavaria, Germany.
Oliver ZimmerDepartment of Pharmaceutical Technology, University of Regensburg, 93053 Regensburg, Bavaria, Germany.
Steffen PockesDepartment of Medicinal Chemistry I, University of Regensburg, 93053 Regensburg, Bavaria, Germany.ORCID 0000-0002-2211-9868
Achim GoepferichDepartment of Pharmaceutical Technology, University of Regensburg, 93053 Regensburg, Bavaria, Germany.ORCID 0000-0002-7646-0252

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A major bottleneck diminishing the therapeutic efficacy of various drugs is that only small proportions of the administered dose reach the site of action. One promising approach to increase the drug amount in the target tissue is the delivery via nanoparticles (NPs) modified with ligands of cell surface receptors for the selective identification of target cells. However, since receptor binding can unintentionally trigger intracellular signaling cascades, our objective was to develop a receptor-independent way of NP uptake. Cell-penetrating peptides (CPPs) are an attractive tool since they allow efficient cell membrane crossing. So far, their applicability is severely limited as their uptake-promoting ability is nonspecific. Therefore, we aimed to achieve a conditional CPP-mediated NP internalization exclusively into target cells. We synthesized different CPP candidates and investigated their influence on nanoparticle stability, ζ-potential, and uptake characteristics in a core-shell nanoparticle system consisting of poly(lactid-

Indexed as

Cell-Penetrating PeptidesNanoparticlesHumansPolyethylene GlycolsPolylactic Acid-Polyglycolic Acid CopolymerCell-Penetrating PeptidesPolyethylene GlycolsPolylactic Acid-Polyglycolic Acid Copolymercharge-mediated uptakenanoparticle surface chargenanoparticle targetingpolyargininepolycationicpolymer nanoparticlessequential uptakeTAT

Identifiers

PMID39010308
PMCPMC11284753

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.